口服基础胰岛素I338与皮下甘精胰岛素在2型糖尿病中的疗效与安全性:随机双盲2期试验
这项2期随机双盲双模拟试验在德国两个研究中心纳入50例胰岛素初治的2型糖尿病患者,比较每日一次口服I338与皮下甘精胰岛素治疗8周的效果。但因I338所需剂量高、商业化生产不可行,该口服胰岛素项目已停止开发。
要点
- 口服I338与皮下甘精胰岛素在8周时空腹血糖降幅无显著差异。
- 两组不良事件多为轻度,低血糖发生率低且无严重低血糖事件。
- 因I338剂量高、商业化生产不可行,该项目已停止进一步开发。
核心结论
- 口服I338可安全改善胰岛素初治2型糖尿病患者的血糖控制,与皮下甘精胰岛素相比无显著差异。
- 因I338所需剂量高、大规模生产商业不可行,该口服胰岛素项目已停止开发。
研究设计与样本
- 2期、8周、随机、双盲、双模拟、阳性对照、平行组试验,在德国两个研究中心完成。
- 50例患者按1:1随机分配至I338组(n=25)或甘精胰岛素组(n=25),按基线口服降糖药治疗分层。
- 主要终点为8周时空腹血糖的治疗差异,分析集为所有随机分配且至少接受一次试验药物的患者。
主要发现
- 不良事件发生率:I338组15例(60%),甘精胰岛素组17例(68%);最常见为腹泻(每组各3例[12%])和鼻咽炎(I338组5例[20%],甘精胰岛素组2例[8%])。
- 低血糖事件:I338组7次,甘精胰岛素组11次,均无严重低血糖事件。
关键数值与推荐
- 推荐每日起始剂量:I338为2700 nmol,甘精胰岛素为10 U。
临床怎么用
- 口服I338在胰岛素初治2型糖尿病患者中可安全有效地降低空腹血糖,与甘精胰岛素疗效相当。
- 该口服胰岛素项目因剂量高、商业化生产不可行已停止开发,目前不适用于临床处方。
- 未来需改进口服胰岛素制剂技术以降低剂量需求并实现商业化生产。
局限性
- 样本量小(共50例),试验周期短(8周),为2期探索性研究。
- 仅在德国两个研究中心开展,结果外推性有限。
- 该项目因商业化生产不可行已停止开发,无法获得长期疗效与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral insulin 338 (I338) is a long-acting, basal insulin analogue formulated in a tablet with the absorption-enhancer sodium caprate. We investigated the efficacy and safety of I338 versus subcutaneous insulin glargine (IGlar) in patients with type 2 diabetes. METHODS: This was a phase 2, 8-week, randomised, double-blind, double-dummy, active-controlled, parallel trial completed at two research institutes in Germany. Insulin-naive adult patients with type 2 diabetes, inadequately controlled on metformin monotherapy or combined with other oral antidiabetic drugs (HbA1c 7·0-10·0%; BMI 25·0-40·0 kg/m2), were randomly assigned (1:1) to receive once-daily I338 plus subcutaneous placebo (I338 group) or once-daily IGlar plus oral placebo (IGlar group). Randomisation occurred by interactive web response system stratified by baseline treatment with oral antidiabetic drugs. Patients and investigators were masked to treatment assignment. Weekly insulin dose titration aimed to achieve a self-measured fasting plasma glucose (FPG) concentration of 4·4-7·0 mmol/L. The recommended daily starting doses were 2700 nmol I338 or 10 U IGlar, and maximum allowed doses throughout the trial were 16 200 nmol I338 or 60 U IGlar. The primary endpoint was treatment difference in FPG concentration at 8 weeks for all randomly assigned patients receiving at least one dose of trial product (ie, the full analysis set). The trial has been completed and is registered at ClinicalTrials.gov, number NCT02470039. FINDINGS: Between June 1, 2015, and Oct 19, 2015, 82 patients were screened for eligibility and 50 patients were randomly assigned to the I338 group (n=25) or the IGlar group (n=25). Mean FPG concentration at baseline was 9·7 (SD 2·8) in the I338 group and 9·1 (1·7) in the IGlar group. Least square mean FPG concentration at 8 weeks was 7·1 mmol/L (95% CI 6·4-7·8) in the I338 group and 6·8 mmol/L (6·5-7·1) in the IGlar group, with no significant treatment difference (0·3 mmol/L [-0·5 to 1·1]; p=0·46). I338 and IGlar were well tolerated by patients. Adverse events were reported in 15 (60%) patients in the I338 group and 17 (68%) patients in the IGlar group. The most common adverse events were diarrhoea (three [12%] patients in each group) and nasopharyngitis (five [20%] in the I338 group and two [8%] in the IGlar group). Most adverse events were graded mild (47 of 68 events), and no severe adverse events were reported. One patient in the IGlar group had a treatment-emergent serious adverse event (urogenital haemorrhage of moderate intensity, assessed by the investigator as unlikely to be related to treatment; the patient recovered). Incidence of hypoglycaemia was low in both groups (n=7 events in the I338 group; n=11 in the IGlar group), with no severe episodes. INTERPRETATION: I338 can safely improve glycaemic control in insulin-naive patients with type 2 diabetes with no evidence of a difference compared with insulin glargine, a widely used subcutaneously administered basal insulin. Further development of this particular oral insulin project was discontinued because I338 doses were high and, therefore, production of the required quantities of I338 for wide public use was deemed not commercially viable. Improvement of technologies involved in the product's development is the focus of ongoing research. FUNDING: Novo Nordisk.
引用
- Halberg IB, Lyby K, Wassermann K, et al. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. Lancet Diabetes Endocrinol. 2019. PMID: 30679095. doi:10.1016/S2213-8587(18)30372-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。